<DOC>
	<DOCNO>NCT00053963</DOCNO>
	<brief_summary>This phase I trial study side effect best dose FR901228 treat child refractory recurrent solid tumor leukemia . Drugs use chemotherapy use different way stop cancer cell divide stop growing die</brief_summary>
	<brief_title>FR901228 Treating Children With Refractory Recurrent Solid Tumors Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose ( MTD ) FR901228 ( depsipeptide ) pediatric patient refractory recurrent solid tumor . II . Determine dose-limiting toxic effect drug patient . III . Determine pharmacokinetics drug patient . IV . Assess tolerability drug solid tumor MTD patient refractory recurrent leukemia . V. Determine , preliminarily , antitumor activity drug patient . OUTLINE : This dose-escalation , multicenter study . Patients receive FR901228 ( depsipeptide ) IV 4 hour day 1 , 8 , 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient solid tumor receive escalate dos FR901228 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Cohorts 3 patient ( 6 patient total ) leukemia receive FR901228 MTD . Patients follow survival .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Ependymoma</mesh_term>
	<mesh_term>Meningioma</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Craniopharyngioma</mesh_term>
	<mesh_term>Adamantinoma</mesh_term>
	<mesh_term>Choroid Plexus Neoplasms</mesh_term>
	<mesh_term>Optic Nerve Glioma</mesh_term>
	<mesh_term>Spinal Cord Neoplasms</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<criteria>Histologically confirm malignancy Extracranial solid tumor brain tumors* Diagnosis leukemia allow maximum tolerated dose determine , include follow : Acute lymphoblastic leukemia Acute myelogenous leukemia Chronic myelogenous leukemia blast crisis Disease must refractory conventional therapy effective conventional therapy exist CNS tumor result neurological deficit must stable 2 week study entry Performance status Karnofsky 60100 % ( 10 year old ) Performance status Lansky 60100 % ( 10 year old ) At least 8 week Absolute neutrophil count least 1,000/mm^3 ( solid tumor patient without bone marrow involvement ) Platelet count least 100,000/mm^3 ( solid tumor patient without bone marrow involvement ; platelet transfusion independent ) OR 20,000/mm^3 ( leukemia patient ; platelet transfusion allow ) Hemoglobin least 8.0 g/dL ( RBC transfusion allow ) Bilirubin great 1.5 time upper limit normal ( ULN ) ALT great 5 time ULN Albumin least 2 g/dL Glomerular filtration rate least 70 mL/min Creatinine base age follow : No great 0.8 mg/dL ( patient 5 year age ) No great 1.0 mg/dL ( patient 6 10 year age ) No great 1.2 mg/dL ( patient 11 15 year age ) No great 1.5 mg/dL ( patient 15 year age ) Calcium normal ( without supplementation ) Shortening fraction least 27 % echocardiogram OR ejection fraction least 50 % MUGA No symptomatic congestive heart failure No uncontrolled cardiac arrhythmia QTc le 450 msec No evidence dyspnea rest No exercise intolerance Pulse oximetry great 94 % Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 1 month completion study treatment Magnesium potassium normal ( without supplementation ) No uncontrolled seizure disorder No uncontrolled infection No graftvshost disease No seizure disorder unless well control enzymeinducing anticonvulsant At least 1 week since prior growth factor At least 3 week since prior biologic therapy immunotherapy recover At least 6 month since prior allogeneic stem cell transplantation No concurrent routine prophylactic growth factor At least 3 week since prior myelosuppressive chemotherapy ( 4 week nitrosoureas ) recover No prior FR901228 ( depsipeptide ) No concurrent anticancer chemotherapy Concurrent dexamethasone CNS tumor allow stable dose decrease dose least 1 week study entry Recovered prior radiotherapy At least 2 week since prior local palliative radiotherapy ( small port ) At least 6 month since prior craniospinal radiotherapy radiotherapy least 50 % pelvis At least 6 week since prior substantial bone marrow radiation More 5 halflife washout period since prior concurrent medication associate prolongation QTc interval No concurrent enzymeinducing anticonvulsant No concurrent hydrochlorothiazide No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>